Tag:

Bristol-Myers Squibb

Latest Headlines

Latest Headlines

Bristol-Myers snags a hep C approval to piggyback on Gilead's blockbuster

Bristol-Myers Squibb, playing catch-up in hepatitis C, picked up FDA approval for a virus-blocking agent to be used in tandem with Sovaldi, Gilead Sciences' blockbuster success.

Bristol-Myers smashes Q2 as hep C meds rake in overseas sales

Here's an earnings trend-buster: Bristol-Myers Squibb trounced expectations for the second quarter and hiked its full-year sales forecast by more than $1 billion.

Bristol-Myers' next-gen HIV med gets FDA 'breakthrough' designation

Bristol-Myers Squibb nabbed a "breakthrough" tag from the FDA for its next-gen HIV therapy aimed at patients who become resistant to the drugs now in use.

Bristol-Myers makes a 'breakthrough' on next-gen HIV therapy

Bristol-Myers Squibb has nabbed a breakthrough therapeutic designation for a next-gen HIV therapy aimed at offering an option for patients who become resistant to the therapies now in use.

Study stopped early as BMS' Opdivo bests Afinitor in kidney cancer

Bristol-Myers Squibb can brag about another success with immunotherapy Opdivo. A late-stage study in advanced kidney cancer will be stopped early, after a monitoring committee flagged improved survival results for Opdivo, compared with the Novartis treatment Afinitor.

Opdivo trial stopped early as BMS med tops Afinitor in kidney cancer

Bristol-Myers Squibb hit a big milestone in its quest to expand use of the immunotherapy Opdivo in a slate of cancer types. In a late-stage kidney cancer study, Opdivo showed a survival advantage over Novartis' Afinitor, prompting a monitoring committee to stop the trial early.

UPDATED: Bristol-Myers flags early success for PhIII Opdivo study in kidney cancer

Bristol-Myers Squibb flagged an early success for its Phase III Opdivo (nivolumab) study for kidney cancer, saying that an independent monitoring group concluded that its closely watched checkpoint inhibitor has beat Afinitor (everolimus) in improving overall survival for advanced patients.

'Modern Family' star signs on with BMS for immuno-oncology awareness

Pharma-watchers may be very familiar with immuno-oncology. But the average American doesn't necessarily know what the term means--or why it's important. Bring on "Modern Family" star Eric Stonestreet.

Bristol-Myers looks to academia to double down on fibrosis R&D

Bristol-Myers Squibb is teaming up with researchers at the Medical University of South Carolina to shed some light on the root causes of fibrotic disease, planning translational studies on a handful of ailments with hopes of spotlighting new treatments.

Biopharma's 10 highest-paid heads of R&D

The year's 10 highest-paid development executives pulled in $124.4 million in total compensation, a roughly 35% jump over 2013's top earners. And while each entrant benefited from meeting individual company goals, the whole group benefited from biopharma's macroeconomic moment in the sun, as the value of stock awards skyrocketed alongside the industry index.